Clinical trials: CMV, open to volunteers
Kidney Diseases, Kidney Injury
ID-ENTITY Trial- Evaluating Serial T-ID Monitoring
To evaluate the association between time-updated CMV and BK viral loads measured monthly by T-ID and the risk of CMV disease and/or biopsy-proven BK virus-associated nephropathy (BKVAN) during the first 12 months following kidney…
- Conditions
- Kidney Diseases, Kidney Injury, BK Virus Infection, CMV
- Trial name
- ID-ENTITY (NCT07393594)
- Testing
- Blood tests, TRAC( cell free DNA) and T-ID
- Where
- 14 sites in United States
- Volunteers
- 1,000 people
- Sponsor
- Transplant Genomics, Inc.
EBV Viremia, CMV Viremia
25BT056: Basket Study of Viral Cytotoxic T Lymphocytes
This study is evaluating the safety and effectiveness of virus-specific cytotoxic T lymphocytes (vCTLs) for treating difficult-to-control viral infections caused by cytomegalovirus (CMV), adenovirus (ADV), Epstein-Barr virus…
- Conditions
- EBV Viremia, CMV Viremia, BK Viremia, Adenovirus
- Trial name
- NCT07873970
- Testing
- Virus-Specific Cytotoxic T Lymphocytes (vCTLs)
- Volunteers
- 35 people
- Sponsor
- Children's Hospital of Philadelphia
Cytomegalovirus Infections, Cytomegalovirus Disease
Letermovir Prophylaxis Duration Guided by CMV-Specific T-cell Monitoring After Allo-HSCT.
The purpose of this study is to evaluate the efficacy and safety of a personalized strategy for discontinuing Letermovir (a drug used to prevent Cytomegalovirus [CMV] infection) based on the recovery of the patient's own immune…
- Conditions
- Cytomegalovirus Infections, Cytomegalovirus Disease, Hematopoietic Stem Cell Transplantation, Graft vs Host Disease
- Trial name
- NCT07569653
- Testing
- CMV-Specific T-cell Guided Letermovir Discontinuation, Standard Letermovir Prophylaxis
- Where
- 12 sites in China
- Volunteers
- 120 people
- Sponsor
- WeiShi
Lymphoma Neoplasms, Myeloma Multiple
Infectious Complications in Hematological Patients Under Treatment With Bispecific Antibodies.
This is a prospective, multicenter, observational cohort study involving patients with hematologic malignancies who are receiving bispecific antibody therapy.
- Conditions
- Lymphoma Neoplasms, Myeloma Multiple, Severe Infection, CMV Reactivation
- Trial name
- NCT07609576
- Where
- 2 sites in Spain
- Volunteers
- 350 people
- Sponsor
- Infanta Leonor University Hospital
BKV Infection, CMV Infection
Evaluation of Safety and Efficacy of Virus Specific T-Cell Administration in Pediatric Patients With Systemic Viral Infection Following Allogeneic Hematopoietic Stem Cell Transplantation.
The goal of this prospective clinical study is to evaluate the safety and efficacy of Multi-Virus Specific T cells (LB-DTK-MV) in pediatric patients with systemic viral infection, including CMV, EBV, and BKV, after allogeneic…
- Conditions
- BKV Infection, CMV Infection, EBV Infection
- Trial name
- NCT07685457
- Testing
- LB-DTK-MV
- Where
- South Korea
- Volunteers
- 6 people
- Sponsor
- LucasBio
Cytomegaloviral Infection, Hematopoietic Cell Transplant Recipient
Multi-antigen CMV-Modified Vaccinia Ankara Vaccine in Treating Pediatric Patients With Positive Cytomegalovirus Undergoing Donor Stem Cell Transplant
This phase I/II trial studies the side effects and best dose of multi-antigen cytomegalovirus (CMV)-modified vaccinia ankara vaccine and to see how well it works in treating pediatric patients with positive cytomegalovirus who…
- Trial name
- NCT03354728
- Testing
- Laboratory Biomarker Analysis, Multi-peptide CMV-Modified Vaccinia Ankara Vaccine
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- City of Hope Medical Center
Allogeneic Stem Cell Transplant, Viral Infection
Donor-Derived Viral Specific T-cells (VSTs)
In this research study, the investigators want to learn more about the use of donor-derived viral specific T-cells (VSTs) to treat viral infections that occur after allogeneic stem cell transplant.
- Conditions
- Allogeneic Stem Cell Transplant, Viral Infection, Viral Reactivation
- Trial name
- VSTs (NCT02048332)
- Testing
- Viral specific VST Infusion
- Where
- 3 sites in United States
- Volunteers
- 1,000 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Pregnant Women, CMV Infected Fetuses
Prenatal Treatment of Congenital Cytomegalovirus Infection With Letermovir Versus Valaciclovir
The investigators' hypothesis is that maternal treatment with Letermovir will inhibit fetal CMV replication better than Valaciclovir in infected fetuses and lead to a higher proportion of negative CMV PCR at birth in neonatal…
- Trial name
- CYMEVAL3-step2 (NCT05446571)
- Testing
- Letermovir, Valacyclovir
- Where
- France
- Volunteers
- 46 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Cytomegalovirus (CMV)
A Study of LIVTENCITY (Maribavir) in Adults With Cytomegalovirus (CMV) Infection After Transplantation in South Korea
Cytomegalovirus (CMV) is a common virus that infects many people. It can cause serious illness in people with weak immune systems especially in those undergoing transplants.
- Trial name
- NCT06555432
- Testing
- LIVTENCITY
- Where
- South Korea
- Volunteers
- 168 people
- Sponsor
- Takeda
Infections, Cytomegalovirus
A Prospective Single-Arm Observational Study of Maribavir for the Treatment of Post Hematopoietic Stem Cell Transplantation Cytomegalovirus Infection
The main aim of this study is to check the effectiveness and safety of maribavir for the treatment of CMV infection after HSCT in Chinese patients in real-world settings.
- Trial name
- NCT07141095
- Testing
- maribavir
- Where
- China
- Volunteers
- 17 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Cytomegalovirus Infections
QuantiFERON-CMV Test in a Prediction for Colic Cytomegalovirus Reactivation During Ulcerative Colitis
CytoMegaloVirus (CMV) infection impairs evolution of Ulcerative Colitis (UC) leading to more severe and resistant to immunosuppressive therapies flare-up.
- Trial name
- RECOHFERRON (NCT04030676)
- Testing
- Biopsies, Blood samples
- Where
- 2 sites in France
- Volunteers
- 196 people
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
Human Cytomegalovirus (HCMV)
Immunological and Virological Prognostic Markers of Human Cytomegalovirus (HCMV) Congenital Infection in Pregnant Women With Primary HCMV Infection.
Human cytomegalovirus (HCMV) establishes a lifelong relationship with its host: primary infection is followed by a latency phase with intermittent reactivation episodes, despite a robust, long-lasting immune response.
- Trial name
- NCT07477925
- Where
- Italy
- Volunteers
- 90 people
- Sponsor
- Fondazione IRCCS Policlinico San Matteo di Pavia
Cytomegalovirus (CMV), HIV (Human Immunodeficiency Virus)
A Clinical Study to Evaluate the Safety and Immunogenicity of a Higher Dose of the Study Vaccine, VIR-1388, in HCMV-seropositive Adult Participants Without HIV
This study is to test an experimental HIV Vaccine. About 12 participants, aged 18-55 years and who already have cytomegalovirus (CMV) will take part in this study.
- Trial name
- NCT07801456
- Testing
- VIR-1388
- Where
- 2 sites in United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Cytomegalovirus Infections, Primary Immune Deficiency Disorder
Virus Specific Cytotoxic T-Lymphocytes (CTLs) for Refractory Cytomegalovirus (CMV)
CMV cytotoxic T cells (CTLs) manufactured with the Miltenyi CliniMACS Prodigy Cytokine Capture System will be administered in children, adolescents and young adults (CAYA) with refractory cytomegalovirus (CMV) infection post…
- Trial name
- NCT03266640
- Testing
- viral specific cytotoxic t-lymphocytes
- Where
- 9 sites in United States
- Volunteers
- 20 people
- Sponsor
- New York Medical College
Immunoglobulin Prophylaxis, Cytomegalovirus Infections
Immunoglobiulin-specific Prophylaxis of Citomegalovirus Infections in Immunocompromised Children Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
Human cytomegalovirus (CMV) is a globally prevalent, human-specific herpesvirus characterised by a lifelong latency after primary infection, an often asymptomatic reactivation and affecting up to 100% of adults based on region…
- Conditions
- Immunoglobulin Prophylaxis, Cytomegalovirus Infections, Allogeneic Hematopoietic Stem Cell Transplantation, Transplant-Related Disorder
- Trial name
- NCT07013370
- Testing
- Anti-CMV immunoglobulins [Megalotect (R)]
- Where
- Italy
- Volunteers
- 150 people
- Sponsor
- Antonello Di Paolo, M.D., Ph.D.
CMV Infection
Reducing Post-Letermovir CMV Infection: Efficacy of an Immune-Reconstitution-Based Scoring System to Guide Prophylaxis Duration
With the increasing use of letermovir and considering that haploidentical hematopoietic stem cell transplantation (haplo-HSCT) predominates in China alongside a high CMV seroprevalence in the population, multiple domestic centers…
- Trial name
- NCT07443501
- Volunteers
- 1,114 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Cytomegalovirus Infections, Solid Organ Transplantation Recipient
CMV Refractory and Resistant Infection in Solid Organ Transplant Recipients in Argentina
This study will describe the frequency and characteristics of refractory and resistant cytomegalovirus (CMV) infection in adults who received a solid organ transplant in Argentina between 2017 and 2024.
- Conditions
- Cytomegalovirus Infections, Solid Organ Transplantation Recipient, Solid Organ Transplantation
- Trial name
- NCT07787767
- Where
- Argentina
- Volunteers
- 200 people
- Sponsor
- Hospital Italiano de Buenos Aires
Lung Diseases
Prophylaxis Guided by Cytomegalovirus-specific T Cell Immunity to Prevent Cytomegalovirus Disease in Lung Transplant Recipients
The purpose of this study is to evaluate the clinical outcomes of Cytomegalovirus (CMV) virus in the participants' body. Therefore, the study team will follow the participants' immunological response based on the Cytomegalovirus…
- Trial name
- NCT06494033
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- University of Miami
Cytomegalovirus (CMV) Infection
CytoGam for CMV Infection or Disease in Solid Organ Transplant Recipients
Cytomegalovirus (CMV) is a significant opportunistic pathogen and a major cause of morbidity and mortality in solid organ transplant recipients.
- Trial name
- NCT07009548
- Testing
- Cytogam
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Fernanda P Silveira, MD, MS
Congenital CMV Infection
Evaluation of Long-term Efficacy of 4 to 6-month Course Antiviral Therapy for Neurodevelopmental Impairments Caused by Congenital Cytomegalovirus Infection
Title: Evaluation of Long-term Efficacy of 4-month versus 6-month Course Antiviral Therapy for Neurodevelopmental Impairment Caused by Congenital CMV Infection: A Multicenter, Randomized, Controlled, Non-inferiority Clinical…
- Trial name
- NCT07450365
- Testing
- Intravenous ganciclovir (6 mg/kg, twice daily) or oral valganciclovir (16 mg/kg, twice daily) was administered for a treatment course of 4 months., Patients received a 6-month course of anti-CMV therapy. The treatment regimen consisted of either intravenous ganciclovir (6 mg/kg, twice daily) or oral valganciclovir (16 mg/kg, twice daily).
- Volunteers
- 150 people
- Sponsor
- Hu Bofei